These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Correlation of membrane type I matrix metalloproteinase (MT1-MMP) expression with clinicomorphological features of tumor front in squamous cell carcinoma of the larynx]. Author: Starska K, Stasikowska O, Lukomski M, Lewy-Trenda I. Journal: Pol Merkur Lekarski; 2007 Sep; 23(135):188-91. PubMed ID: 18080692. Abstract: UNLABELLED: Matrix metalloproteases (MMPs) are proteolytic enzymes contribute to tumor expansion by degrading components of the extracellular matrix. MPPs play a key role in tumor invasion and metastases of various cancers and head and neck carcinoma as well. The aim of this study was to investigate MT1-MMP expression in squamous cell carcinoma of the larynx to relate these levels of expression to clinicohistological features of the tumor and lymph nodes e.g. TNM, nodal micrometastases, tumor front grading and 3- and 5-year survival. MATERIAL AND METHODS: The study included 22 patients with laryngeal cancer surgical treated in ENT Department Medical University of Lódź between 1998 and 1999. The expression of MT1-MMP was evaluated immunohistochemically using monoclonal antibodies anti-MT1-MMP (Mouse Anti-Human MT1-MMP, MAB3319 Chemicon). The polyclonal antibodies anti-CK for developing nodal micrometastases was used as well. RESULTS: Positive MT1-MMP expression in 68.2% cases was observed. Immunoexpression of MT1-MMP in advanced laryngeal carcinoma as indicator for 3-year survival was noted. In addition, levels of staining correlated with number of mitoses in tumor front and plasmocytolymphatic infiltration in its environment. CONCLUSIONS: The expression of MT1-MMP in tumor front appears to play an important role in determining prognosis in patients with carcinoma of the larynx.[Abstract] [Full Text] [Related] [New Search]